| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 21, 2003
Accepted on September 26, 2003
1 Division of Pediatric Endocrinology and Diabetology, University of Geneva School of Medicine, 1211 Geneva 14, Switzerland; Instituto Tecnológico e Nuclear, 2685 Sacavém, Portugal; Division of Hypertension, University of Lausanne Medical School, 1011 Lausanne, Switzerland; Dept. of Biochemistry, Howard Hughes Medical Institute, Seattle, WA98195, USA.
* To whom correspondence should be addressed. E-mail: Michel.Aubert{at}medecine.unige.ch.
Neuropeptide Y (NPY) is a powerful orexigenic neurotransmitter. The NPY Y1 and Y5 receptors have been implicated in mediating the appetite-stimulating activity of NPY. To further investigate the importance of these two receptors in NPY-induced hyperphagia following chronic central administration, we used mice lacking either Npy1r or Npy5r expression. NPY infusion into the lateral ventricle of wild-type mice stimulated food intake and induced obesity over a 7-day period. Fat pad weight as well as plasma insulin, leptin, and corticosterone levels were strongly increased in NPY-treated mice. In addition, NPY infusion resulted in a significant decrease in hypothalamic NPY and POMC expression. Interestingly, the lack of either Npy1r or Npy5r expression in knockouts did not affect such feeding response to chronic NPY infusion. Moreover, the obesity syndrome that developed in these animals was similar to that seen in wild-types. Taken together these data strongly suggest biological redundancies between Y1 and Y5 receptor signaling in the NPY-mediated control of food intake.
This article has been cited by other articles:
 |
|
 |
|
  M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-J. D. Lin, A. Sainsbury, N. J. Lee, D. Boey, M. Couzens, R. Enriquez, K. Slack, R. Bland, M. J. During, and H. Herzog Combined Deletion of Y1, Y2, and Y4 Receptors Prevents Hypothalamic Neuropeptide Y Overexpression-Induced Hyperinsulinemia despite Persistence of Hyperphagia and Obesity Endocrinology, November 1, 2006; 147(11): 5094 - 5101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kakui, J. Tanaka, Y. Tabata, K. Asai, N. Masuda, T. Miyara, Y. Nakatani, F. Ohsawa, N. Nishikawa, M. Sugai, et al. Pharmacological Characterization and Feeding-Suppressive Property of FMS586 [3-(5,6,7,8-Tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea Hydrochloride], a Novel, Selective, and Orally Active Antagonist for Neuropeptide Y Y5 Receptor J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 562 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ste. Marie, S. Luquet, T. B. Cole, and R. D. Palmiter Modulation of neuropeptide Y expression in adult mice does not affect feeding PNAS, December 20, 2005; 102(51): 18632 - 18637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stanley, K. Wynne, B. McGowan, and S. Bloom Hormonal Regulation of Food Intake Physiol Rev, October 1, 2005; 85(4): 1131 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Porte Jr., D. G. Baskin, and M. W. Schwartz Insulin Signaling in the Central Nervous System: A Critical Role in Metabolic Homeostasis and Disease From C. elegans to Humans Diabetes, May 1, 2005; 54(5): 1264 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wynne, S. Stanley, B. McGowan, and S. Bloom Appetite control J. Endocrinol., February 1, 2005; 184(2): 291 - 318. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
